Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome.
A 19-year-old male patient with virus associated hemophagocytic syndrome (VAHS) began receiving chemotherapy including etoposide (cumulative dose of 900 mg/m2 intravenously) and Ara-C (cumulative dose of 360 mg/m2 intravenously) in July 1994. He achieved complete remission, but developed acute myelomonocytic leukemia (AML, FAB M4) with t(9;11)(p22;q23) in March 1997 and a rearrangement of the MLL gene was also recognized. The MLL gene rearrangement is closely associated with secondary leukemia with an 11q23 translocation. It is highly likely that this case of AML was caused by the cytostatic treatment the patient received, including etoposide for VAHS.
Takahashi
T
T
First Department of Internal Medicine, Saitama Medical School, Japan.
Yagasaki
F
F
Endo
K
K
Takahashi
M
M
Itoh
Y
Y
Kawai
N
N
Kusumoto
S
S
Murohashi
I
I
Bessho
M
M
Hirashima
K
K
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000627:therapeutic use*; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced* / Q000235:genetics; D008297:Male; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005047:Etoposide